Cellectar Biosciences

CLRB

Market cap $12.7M

FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time.

Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) for Iopofosine I 131 as a Treatment for Waldenström Macroglobulinemia FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a broad expansion of its global intellectual property (IP) estate, including newly issued patents across Europe, Asia-Pacific, the Middle East, and the Americas.

Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026

Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors

Cellectar Biosciences, Inc. ( CLRB ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor - Chief Operating Officer Conference Call Participants Anne Marie Fields Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025.

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP)

CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models

Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors

Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25

FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September.